Genomic Testing Cooperative, LCA
175 Technology Dr, Suite 100, Irvine, CA 92618
Tel: 1-949-540-9421 | Fax: 1-949-301-9719
Toll-Free: 1-866-484-8870

CLIA # 05D2111917 CAP # 9441574
Laboratory Director: Maher Albitar, MD
genomictestingcooperative.com

TEST REQUISITION

Client Information

Account #:
Account Name:
Phone:
Fax:
Street Address:
City:
State: Zip:

Billing Information for Orders by Non-Members

Required: Please include face sheet and front/back of patient's insurance card.

Specimen Origin (Must Choose 1): □ Hospital Patient (in) □ Hospital Patient (out) □ Non-Hospital Patient

Bill to:
□ Client Bill □ Insurance □ Medicare
□ Medicaid
□ Patient/Self-Pay
□ Bill charges to other Hospital/Facility:
_____
_____
□ ICD code (required) _____

Diagnosis/Patient History

Solid Tumors

Type:
□ NSCLC □ Colorectal Cancer □ Melanoma
□ Ovarian □ Breast □ Brain □ Prostate
□ Endometrial □ Stomach □ Esophageal
□ Other, Specify:
_____
_____

Stage:
□ Primary □ Metastasis
If Metastasis, list Primary:
_____
□ Relapse □ ICD code _____
□ Other Stage _____
Please include most recent copy of pathology report

Hematologic Tumors

Type:
□ AML □ MDS □ MPN □ DLBCL □ ALL
□ CLL □ Lymphoma □ Myeloma
□ Other, Specify:
_____
_____

Other Relevant Information:
Ethnicity: _____
Family History _____
Other: _____
Please include most recent copy of pathology report and CBC

Patient Information

Last Name:
First Name:
M.I.: Gender: □ Male □ Female
Date of Birth: (mm/dd/yyyy)
Medical Record #:
Requisition completed by:
Date:
Ordering Physician (please print: Last, First):
NPI#:
Treating Physician (please print: Last, First):

The undersigned certifies that he/she is licensed to order the test(s) listed below and that such test(s) are medically necessary for the care/treatment of this patient.

Authorized Signature:
Date:

Specimen Information

Collection Date: Time:
Specimen ID/ Block ID:
Fixative/Preservative: □ 10% Neutral Buffered Formalin □ Other
Hospital Discharge Date:
Body Site:

□ Peripheral Blood: EDTA-Purple Top(s) _____ Other _____
□ Bone Marrow: EDTA-Purple Top(s) _____ Other _____
□ Fluid: CSF _____ Pleural _____ Other: _____
□ FNA cell block: _____
□ Slides # _____ Unstained _____ Stained _____
□ H&E _____ □ Paraffin Block(s) #: _____

Test Selection

Solid Tumors Tests

□ **GTC**-Solid Tumor Profile
□ **GTC**-Solid Tumor Fusion/Expression Profile
□ **GTC**-Solid Tumor Profile Plus Expression
□ **GTC**-Liquid Biopsy, Solid Tumor Monitoring

Hematologic Tumors Tests

□ **GTC**-Hematology Profile
□ **GTC**-Hematology Fusion/Expression Profile
□ **GTC**-Hematology Profile Plus Fusion/Expression
□ **GTC**-Liquid Biopsy, Hematology Profile
□ **Other Test-** _____

Genomic Testing Cooperative, LCA
175 Technology Dr, Suite 100, Irvine, CA 92618
Tel: 1-949-540-9421 | Fax: 1-949-301-9719
Toll-Free: 1-866-484-8870

CLIA # 05D2111917 CAP # 9441574
Laboratory Director: Maher Albitar, MD
genomictestingcooperative.com

GTC-Solid Tumor Profile

This test is designed to profile the molecular abnormalities in various solid tumors including glioblastoma and sarcoma and to provide physicians with clinically actionable information. This profiling covers abnormalities in single neucleotide abnormalities and indels in 434 genes along with testing for microsatellite instability (MSI) and tumor mutational burden (TMB). The provided information help in determining prognosis, design therapeutic approach and predict response to therapy. GTC-Solid Tumor Profile Plus test combines the analysis of DNA with RNA analysis to detect fusion genes and expression.

Genes Tested for Abnormalities in coding sequence*																
ABCB7	AURKB	C15ORF41	CEBPA	DICER1	FANCC	FLT3	GRIN2A	IRF2	LMO1	MSH2	NTRK1	POLE	RANBP2	SETD2	STAT4	TSC2
ABL1	AURKC	CALR	CHD2	DOT1L	FANCD2	FLT4	GRM3	IRF4	LPIN2	MSH6	NTRK2	POT1	RARA	SF3B1	STAT6	TSHR
ABL2	AXIN1	CARD11	CHD4	EED	FANCE	FOXL2	GSK3B	IRS2	LRP1B	MTOR	NTRK3	PPM1D	RB1	SLIT2	STK11	U2AF1
ACD	AXIN2	CBFB	CHEK1	EGFR	FANCF	FOXP1	GSKIP	JAGN1	LYN	MUTYH	NUP93	PPP2R1A	RBBP6	SLX4	SUFU	U2AF2
ACVR1B	AXL	CBL	CHEK2	EGLN1	FANCG	FRS2	H3F3A	JAK1	LYST	MVK	PAK3	PRDM1	RBM10	SMAD2	SUZ12	VEGFA
ADA	B2M	CBLB	CIC	ELANE	FANCI	FUBP1	HAX1	JAK2	LZTR1	MYC	PALB2	PREX2	RBM8A	SMAD3	SYK	VHL
AK2	BAP1	CBLC	CREBBP	EP300	FANCL	G6PC3	HGF	JAK3	MAGI2	MYCL	PARK2	PRKAR1A	RET	SMAD4	TAF1	WAS
AKT1	BARD1	CCND1	CRKL	EPAS1	FANCM	GABRA6	HIST1H3B	JUN	MAP2K1	MYCN	PAX5	PRKCI	RHEB	SMAD9	TAL1	WHSC1
AKT2	BCL2	CCND2	CRLF2	EPCAM	FAS	GALNT12	HNF1A	KAT6A	MAP2K2	MYD88	PBRM1	PRKDC	RHOA	SMAD9L	TBX3	WISP3
AKT3	BCL2L1	CCND3	CSF1R	EPHA3	FAT1	GATA1	HOXA11	KDM5A	MAP2K4	NBN	PDCD1LG2	PRSS1	RICTOR	SMARCA4	TCF3	WT1
ALK	BCL2L2	CCNE1	CSF3R	EPHA5	FBXW7	GATA2	HOXB13	KDM5C	MAP3K1	NF1	PDGFRA	PRSS8	RIT1	SMARCB1	TCIRG1	XPO1
AMER1	BCL6	CD274	CTC1	EPHA7	FGF10	GATA3	HRAS	KDM6A	MAP3K14	NF2	PDGFRB	PSTPIP1	RNF168	SMC1A	TERC	XRCC2
ANKRD26	BCOR	CD79A	CTCF	EPHB1	FGF14	GATA4	HSD3B1	KDR	MAPK1	NFE2L2	PDK1	PTCH1	RNF43	SMC3	TERF1	XRCC3
APC	BCORL1	CD79B	CTNNA1	ERBB2	FGF19	GATA6	HSP90AA1	KEAP1	MCL1	NFKBIA	PHF6	PTEN	ROS1	SMO	TERF2	ZBTB2
AR	BCR	CDAN1	CTNNB1	ERBB3	FGF23	GEN1	ID3	KEL	MDM2	NHP2	PIK3C2B	PTPN11	RPTOR	SNCAIP	TERF2IP	ZNF217
ARAF	BIRC3	CDC73	CUL3	ERBB4	FGF3	GFI1	IDH1	KIF23	MDM4	NKX2-1	PIK3CA	QKI	RTEL1	SOCS1	TERT	ZNF703
ARFRP1	BLM	CDH1	CUX1	ERCC4	FGF4	GFI1B	IDH2	KIT	MED12	NLRP3	PIK3CB	RAB27A	RUNX1	SOX10	TET2	ZRSR2
ARID1A	BMPR1A	CDK12	CXCR4	ERG	FGF6	GID4	IGF1R	KLF1	MEF2B	NME1	PIK3CG	RAC1	RUNX1T1	SOX2	TGFBR2	
ARID1B	BRAF	CDK4	CYLD	ERRFI1	FGFR1	GLI1	IGF2	KLHL6	MEFV	NOP10	PIK3R1	RAD21	SBDS	SOX9	TNFAIP3	
ARID2	BRCA1	CDK6	DAXX	ESR1	FGFR2	GLI2	IKBKE	KLLN	MEN1	NOTCH1	PIK3R2	RAD50	SBF2	SPEN	TNFRSF14	
ASXL1	BRCA2	CDK8	DDR2	ETV6	FGFR3	GNA11	IKZF1	KMT2A	Merged	NOTCH2	PIM1	RAD51	SDHA	SPOP	TNFRSF1A	
ATG2B	BRD4	CDKN1A	DDX11	EXO1	FGFR4	GNA13	IKZF3	KMT2B	MET	NOTCH3	PLCG1	RAD51B	SDHB	SPTA1	TOP1	
ATM	BRIP1	CDKN1B	DDX41	EZH2	FH	GNAQ	IL2RG	KMT2C	MITF	NPM1	PLCG2	RAD51C	SDHC	SRC	TOP2A	
ATR	BTG1	CDKN2A	DKC1	FAM175A	FLCN	GNAS	IL7R	KMT2D	MLH1	NRAS	PMS1	RAD51D	SDHD	SRSF2	TP53	
ATRX	BTK	CDKN2B	DNM2	FAM46C	FLI1	GPR124	INHBA	KRAS	MPL	NROB1	PMS2	RAD54L	SEC23B	STAG2	TRAF3	

* Microsatellite markers BAT25, BAT26, D2S123, D5S346, and D17S250 are included.

GTC-Solid Tumor Fusion/Expression Profile

This test is designed to profile the molecular abnormalities in various solid tumors including glioblastoma and sarcoma and to provide physicians with clinically actionable information. This profiling provides clinically relevant information on translocations and expression of 1,385 cancer-specific genes with a focus on 55 genes implicated in solid tumors. This assay is designed to detect various translocations involving ALK, ROS1, RET, NTRK, genes involved in sarcoma and other neoplasms. In addition, expression of genes of clinical relevance is reported including MYC, PD-L1 and others.

Fusion/Expression													
ABL1	BCL2	CBFB	ERG	FGFR2	FOXO1	IKZF3	MAP3K1	NTRK1	NUP98	PICALM	RHOA	SS18	TCF3
AKT3	BCL6	CIC	ETV6	FGFR3	FUS	JAK2	MECOM	NTRK2	PDGFRA	PML	ROS1	STAT6	TFG
ALK	BRAF	CREBBP	EWSR1	FIP1L1	GLI1	KIAA1549	MYC	NTRK3	PDGFRB	RARA	RUNX1	TAFG	YWHAE
BCL1	CAMTA1	EGFR	FGFR1	FLAG1	HMGA2	KMT2A	NOTCH1	NUP214	PD-L1	RET	RUNX1T1	TAL1	

GTC-Hematology Profile

This test is designed to profile the molecular abnormalities in various leukemias, lymphoma and myeloma. The assay is used for stratifying patients and determining prognosis and selecting therapy. This assay is excellent for confirming the diagnosis of MDS and differentiating it from CCUS, ICUS and CHIP. **GTC-Liquid Biopsy, Hematology** test is the same, but performed on cfDNA in peripheral blood plasma. **GTC-Hematology Plus** combine expression and fusion and provide complete profiling for abnormalities in hematologic neoplasms including the diagnosis of Ph- and Ph-like acute lymphoblastic leukemia, double and triple hit DLBCL, as well as classification of DLBCL as GCB or ABC.

Hematology Genes Tested for Abnormalities in coding sequence												
ABL1	BCL2	CBL	CDKN2C	DICER1	FAS	IDH2	KMT2A	MPL	PAX5	PTCH1	SMAD2	TGFBR2
AKT1	BCL2L1	CBLB	CEBPA	DNMT3A	FBXW7	IGF1R	KMT2B	MRE11A	PBRM1	PTEN	SMAD4	TP53
AKT2	BCL6	CBLC	CHEK1	EP300	FLT3	IKZF1	KMT2C	MTOR	PDGFRA	PTPN11	SMARCA4	TSC1
AKT3	BCOR	CCND1	CHEK2	ERG	GATA1	IKZF3	KMT2D	MUTYH	PDGFRB	RAD21	SMARCB1	TSC2
ALK	BCORL1	CCND3	CIC	ETV6	GATA2	IRF4	KRAS	MYC	PHF6	RAD50	SMC1A	TSHR
AMER1	BCR	CD274	CREBBP	EZH2	GATA3	JAK1	MAP2K1	MYD88	PIK3CA	RAD51	SMO	WT1
APC	BIRC3	CD79A	CRLF2	FAM175A	GEN1	JAK2	MAP2K2	NFKBIA	PIK3R1	RB1	SOCS1	ZNF217
ARID1A	BLM	CD79B	CSF1R	FAM46C	GNAQ	JAK3	MAP2K4	NOTCH1	PIK3R2	RHOA	SRC	ZRSR2
ARID1B	BRAF	CDH1	CSF3R	FANCA	GNAS	KAT6A	MAP3K1	NOTCH2	PIM1	RNF43	SRSF2	MEF2B
ARID2	BRCA1	CDK12	CTNNA1	FANCC	H3F3A	KDM5C	MAP3K14	NOTCH3	PLCG1	RUNX1	STAG2	
ASXL1	BRCA2	CDK4	CTNNB1	FANCD2	HNF1A	KDM6A	MAPK1	NPM1	POLD1	SDHB	STAT3	
ATM	BTK	CDK6	CUX1	FANCE	HOXB13	KDR	MCL1	NRAS	POLE	SETBP1	STK11	
ATRX	CALR	CDKN2A	CXCR4	FANCF	HSP90AA1	KEAP1	MDM2	NSD1	PPM1D	SETD2	TERT	
B2M	CARD11	CDKN2B	DDR2	FANCG	IDH1	KIT	MDM4	PALB2	PPP2R1A	SF3B1	TET2	

GTC-Hematology Fusion/Expression

This test provides clinically relevant information on translocations and expression of 1,385 genes with a focus on 67 specific genes associated with hematologic neoplasms. This assay is designed to detect various translocations involving ABL1, RUNX1, BCL2, RARA, PAX5, JAK2, CBFB and other genes involved in leukemia, lymphoma and myeloma.

Fusion/Expression																
ABL1	ALK	BRAF	CREBBP	EPOR	ETV5	FGFR2	FOXO1	*JAK1*	MAP3K1	NOTCH1	NUP214	PCM1	PICALM	RET	RUNX1T1	TCF3
ABL2	BCL1	CBFB	*CRLF2*	ERG	ETV6	FGFR3	FUS	JAK2	MECOM	NTRK1	NUP98	PDGFRA	PML	RHOA	SS18	TCF3
AKT3	BCL2	*CBL*	*CSF1R*	ETV1	EWSR1	FIP1L1	GLI1	KMT2A	MYC	NTRK2	P2RY8	PDGFRB	*PTK2B*	ROS2	STAT6	TFG
ALK	BCL6	CIC	EGFR	ETV4	*FGFR1*	*FLT3*	IKZF3	KRT18P6	*MYH9*	*NTRK3*	PBX1	PD-L1	RARA	RUNX1	TAL1	*TYK2*